| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 76861 |
CAS: 2348405-93-4，DBCO-PEG4-Val-Ala-PAB-PNP |
85 |
WYQ |
2024-12-19 |
| 76862 |
CAS: 2348405-92-3，DBCO-PEG4-Val-Ala-PAB |
99 |
WYQ |
2024-12-19 |
| 76863 |
cas:2112738-13-1 Mal-amido-PEG2-Val-Cit-PAB-PNP |
98 |
zyl |
2024-12-19 |
| 76864 |
Azido-PEG4-Val-Ala-PAB，分子式：C29H48N8O9 |
89 |
WYQ |
2024-12-19 |
| 76865 |
cas:2055896-86-9，MC-Val-Cit-PAB-tubulysin5a ， ADC试剂 |
99 |
kx |
2024-12-19 |
| 76866 |
Azido-PEG8-Val-Cit-PAB-PNP |
91 |
zyl |
2024-12-19 |
| 76867 |
cas:2055896-83-6，MC-Val-Cit-PAB-carfilzomib ， ADC试剂 |
117 |
kx |
2024-12-19 |
| 76868 |
MAL-di-EG-Val-Cit-PAB-MMAF， ADC试剂 |
93 |
kx |
2024-12-19 |
| 76869 |
cas:2353409-45-5 endo BCN-PEG3-VC-PFP Ester |
112 |
zyl |
2024-12-19 |
| 76870 |
Hydrazone-doxorubicin， ADC试剂 |
186 |
kx |
2024-12-19 |
| 76871 |
DBCO-C4-Val-Cit-PABC-PNP |
98 |
zyl |
2024-12-19 |
| 76872 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
99 |
zyl |
2024-12-19 |
| 76873 |
cas:170908-81-3，DOTA-NHS ester ，1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
87 |
kx |
2024-12-19 |
| 76874 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
89 |
zyl |
2024-12-19 |
| 76875 |
cas:2259318-50-6，MA-PEG4-VA-PBD ， ADC试剂 |
106 |
kx |
2024-12-19 |
| 76876 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
76 |
WYQ |
2024-12-19 |
| 76877 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
92 |
WYQ |
2024-12-19 |
| 76878 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
79 |
kx |
2024-12-19 |
| 76879 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
99 |
wyh |
2024-12-19 |
| 76880 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
94 |
zyl |
2024-12-19 |
| 76881 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
113 |
wyh |
2024-12-19 |
| 76882 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
125 |
zyl |
2024-12-19 |
| 76883 |
Gly3-vc-PAB-MMAE， ADC试剂 |
113 |
kx |
2024-12-19 |
| 76884 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
100 |
WYQ |
2024-12-19 |
| 76885 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
114 |
wyh |
2024-12-19 |
| 76886 |
Azido-PEG4-Val-Ala-PAB-PNP |
115 |
zyl |
2024-12-19 |
| 76887 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
88 |
h |
2024-12-19 |
| 76888 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
96 |
wyh |
2024-12-19 |
| 76889 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
90 |
WYQ |
2024-12-19 |
| 76890 |
MC-PBD， ADC试剂 |
101 |
kx |
2024-12-19 |
| 76891 |
Mal-Val-Ala-PAB的介绍 |
106 |
zyl |
2024-12-19 |
| 76892 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
93 |
h |
2024-12-19 |
| 76893 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
96 |
WYQ |
2024-12-19 |
| 76894 |
Arm-DOTA-B72.3 |
90 |
h |
2024-12-19 |
| 76895 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
108 |
zyl |
2024-12-19 |
| 76896 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
146 |
h |
2024-12-19 |
| 76897 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
101 |
kx |
2024-12-19 |
| 76898 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
99 |
h |
2024-12-19 |
| 76899 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
119 |
WYQ |
2024-12-19 |
| 76900 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
134 |
zyl |
2024-12-19 |
| 76901 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
123 |
kx |
2024-12-19 |
| 76902 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
123 |
wyh |
2024-12-19 |
| 76903 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
89 |
h |
2024-12-19 |
| 76904 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
110 |
h |
2024-12-19 |
| 76905 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
121 |
wyh |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询